Literature DB >> 23590140

Significance of metallothionein expression in liver disease.

Takeaki Nagamine, Katsuyuki Nakajima1.   

Abstract

Hepatic metallothionein (MT) expression, with various isoforms, and varying cellular localizations is a useful marker for clinico-pathogenesis of liver diseases. In acute liver toxicity caused by cadmium, carbon tetrachloride, or acetaminophen, MT plays a protective role, via the scavenging of radical species. In chronic hepatitis C patients, hepatic MT levels appear to be a biological factor associated with the severity of HCV infection, and are associated with a better response to IFN therapy. Transgenic mice that express HBsAg in the liver show hepatocellular damage, inflammation, regeneration, hyperplasia, and, eventually, neoplasia. The MT isoform, MT-1 help mitigate HBV-induced hepatitis. Analysis of MT gene expression in the livers of chronic hepatitis B patients is useful for understanding the features of distinct liver diseases and for judging disease progression. A profound down-regulation of isoform MT-1G in hepatocellular carcinoma was observed in 63% of tumors relative to the adjacent nonmalignant liver. MT has been implicated in the control of p53 folding with zinc exchange. Therefore, it appears MT may play a role in the pathogenesis of hepatocellular carcinoma. Overall MT is linked to a variety of liver diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23590140     DOI: 10.2174/1389201011314040006

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  6 in total

1.  Gene expression and pathway analysis of human hepatocellular carcinoma cells treated with cadmium.

Authors:  Laura Cartularo; Freda Laulicht; Hong Sun; Thomas Kluz; Jonathan H Freedman; Max Costa
Journal:  Toxicol Appl Pharmacol       Date:  2015-08-24       Impact factor: 4.219

2.  Evaluation of metallothionein and Ki-67 expression in chronic cholangiohepatitis in cats.

Authors:  Divya Jose; Andrew L Allen; Barry Blakley; Ahmad Al-Dissi
Journal:  Can J Vet Res       Date:  2021-01       Impact factor: 1.310

3.  Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature.

Authors:  Myung-Ho Kim; Mi-Young Kim; Shadi Salloum; Tongqi Qian; Lai Ping Wong; Min Xu; Yoojin Lee; Stuti G Shroff; Ruslan I Sadreyev; Kathleen E Corey; Thomas F Baumert; Yujin Hoshida; Raymond T Chung
Journal:  Hepatol Commun       Date:  2022-06-16

4.  In silico and experimental analyses predict the therapeutic value of an EZH2 inhibitor GSK343 against hepatocellular carcinoma through the induction of metallothionein genes.

Authors:  Tsang-Pai Liu; Yi-Han Hong; Kwang-Yi Tung; Pei-Ming Yang
Journal:  Oncoscience       Date:  2016-01-29

Review 5.  Micronutrients in Nonalcoholic Fatty Liver Disease Pathogenesis.

Authors:  Octavia Pickett-Blakely; Kimberly Young; Rotonya M Carr
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2018-08-23

6.  Effect of Tff3 Deficiency and ER Stress in the Liver.

Authors:  Kate Šešelja; Iva Bazina; Jessica Welss; Martin Schicht; Friedrich Paulsen; Nikola Bijelić; Edi Rođak; Anita Horvatić; Andrea Gelemanović; Martina Mihalj; Mirela Baus Lončar
Journal:  Int J Mol Sci       Date:  2019-09-06       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.